June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Quantitative and Qualitative Assessment of Retinal Degeneration in Canine Models of Inherited Retinal Diseases Using Spectral Domain Optical Coherence Tomography (SD-OCT)
Author Affiliations & Notes
  • Shin Ae Park
    College of Veterinary Medicine, Michigan State University, Okemos, Michigan, United States
  • Jamie Rhodes
    University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Simone Iwabe
    University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Gui-Shuang Ying
    University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • J. Huang
    University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Andras M Komaromy
    College of Veterinary Medicine, Michigan State University, Okemos, Michigan, United States
  • Footnotes
    Commercial Relationships   Shin Ae Park, None; Jamie Rhodes, None; Simone Iwabe, None; Gui-Shuang Ying, None; J. Huang, None; Andras Komaromy, None
  • Footnotes
    Support  NIH Grants EY006855, EY019304, K12 EY015398, P30 EY001583, Foundation Fighting Blindness
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4869. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Shin Ae Park, Jamie Rhodes, Simone Iwabe, Gui-Shuang Ying, J. Huang, Andras M Komaromy; Quantitative and Qualitative Assessment of Retinal Degeneration in Canine Models of Inherited Retinal Diseases Using Spectral Domain Optical Coherence Tomography (SD-OCT). Invest. Ophthalmol. Vis. Sci. 2017;58(8):4869.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To establish SD-OCT quantification data in well-established canine models of inherited retinal dystrophies: PDE6B-rod-cone dysplasia 1(RCD1: early onset retinitis pigmentosa), PRCD-progressive rod-cone degeneration (PRCD: late onset retinitis pigmentosa), CNGB3-achromatopsia (ACHM), and RPE65-Leber congenital amaurosis (LCA).

Methods : High resolution SD-OCT images (Spectralis, Heidelberg Engineering) of the retina were acquired in 5 planes: temporal (T); superotemporal (ST, including area centralis); superior (S); nasal (N); and inferior (I) in adult dogs with advanced disease: PDE6B-RCD1 (n=4 dogs, median age=1.5yrs); PRCD (n=2, 4.3yrs); RPE65-LCA (n=3, 5.2yrs); CNGB3-ACHM (n=3, 4.2yrs); and wild types (wt, n=6, 5.5yrs). Total, inner (from inner limiting membrane to inner plexiform layer-inner nuclear layer interface), and outer (from inner plexiform layer-inner nuclear layer interface to retinal pigment epithelium-choroid interface) retinal thicknesses and ellipsoid zone were analyzed with univariate ANOVA with post-hoc Tuckey test and Chi-square test, respectively.

Results : Compared to wt the thickness of outer retinal layers was significantly decreased (p<0.01) in all imaging planes with RCD1 (decreased by 50.0%, 51.2%, 57.4%, 57.5%, and 60.6% in T, ST, S, N, and I, respectively), PRCD (35.2%, 12.6%, 22.8%, 44.7%, and 38.1%), and LCA (18.0%, 8.4%, 10.4%, 13.4%, and 19.5%) but not ACHM. Significantly more loss of the outer layer thickness was observed in the I and N planes than the ST and T planes, respectively (p<0.05). No significant thinning was observed in inner retinal layer thickness in any disease model. Dogs with RCD1, PRCD, and LCA had significantly more disrupted ellipsoid zone in the presumed area centralis than wt (p<0.01).

Conclusions : We successfully demonstrated the use of SD-OCT to evaluate changes in the retinal morphology in representative canine models of inherited retinal dystrophies. Our findings are consistent with previously published histologic studies. We believe that SD-OCT will provide valuable in vivo outcome measures in the development of novel therapeutics of retinal disease using canine models. The well preserved inner retina in the late stages of disease bauds well for some of the novel therapeutic modalities.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×